Management of Cardiometabolic Syndrome in the Primary and Secondary Prevention of Cardiovascular Disease

Expert Panel on Detection, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E National Cholesterol Education Program (NCEP) Expert Panel on Detection, 2002, Third report on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Wilson, 2005, Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus, Circulation, 112, 3066, 10.1161/CIRCULATIONAHA.105.539528 Hanley, 2004, Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity, Diabetes, 53, 1773, 10.2337/diabetes.53.7.1773 Ford, 2005, Risk for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome: a summary of the evidence, Diabetes Care, 28, 1769, 10.2337/diacare.28.7.1769 Grundy, 2005, Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404 Alexander, 2003, Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210 Nesto, 2004, Correlation between cardiovascular disease and diabetes mellitus: current concepts, Am J Med, 116, 11s, 10.1016/j.amjmed.2003.10.016 Gami, 2007, Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies, J Am Coll Cardiol, 49, 403, 10.1016/j.jacc.2006.09.032 Ford, 2002, Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey, JAMA, 287, 356, 10.1001/jama.287.3.356 Ford, 2004, Increasing prevalence of the metabolic syndrome among US Adults, Diabetes Care, 27, 2444, 10.2337/diacare.27.10.2444 Lemieux, 2000, Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small dense LDL-C) in men?, Circulation, 102, 179, 10.1161/01.CIR.102.2.179 Carr, 2004, Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome, Diabetes, 53, 2087, 10.2337/diabetes.53.8.2087 Reaven, 1988, Banting lecture 1988. Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diabetes.37.12.1595 Ferrannini, 1991, Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome, Diabetologia, 34, 416, 10.1007/BF00403180 Berneis, 2002, Metabolic origins and clinical significance of LDL-C heterogeneity, J Lipid Res, 43, 1363, 10.1194/jlr.R200004-JLR200 von Eckardstein, 2005, Current understanding of the metabolic and biological actions of HDL-C, Curr Opin Clin Nutr Metab Care, 8, 147, 10.1097/00075197-200503000-00007 Jellinger, 2007, Metabolic consequences of hyperglycemia and insulin resistance, Clin Cornerstone, 8, S30, 10.1016/S1098-3597(07)80019-6 Chobanian, 2003, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Aronson, 2002, How hyperglycemia promotes atherosclerosis: molecular mechanisms, Cardiovasc Diabetol, 1, 1, 10.1186/1475-2840-1-1 Juhan-Vague, 2002, The insulin resistance syndrome: implications for thrombosis and cardiovascular disease, Pathophysiol Haemost Thromb, 32, 269, 10.1159/000073579 Eckel, 2005, The metabolic syndrome, Lancet, 365, 1415, 10.1016/S0140-6736(05)66378-7 Wellen, 2003, Obesity induced inflammatory changes in adipose tissue, J Clin Investig, 112, 1785, 10.1172/JCI20514 Ross, 1999, Atherosclerosis – an inflammatory disease, NEJM, 340, 115, 10.1056/NEJM199901143400207 Pollex, 2006, Genetic determinants of the metabolic syndrome, Nat Clin Pract, 3, 482, 10.1038/ncpcardio0638 WHO George, 2005, The metabolic syndrome – a new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8 Hunt, 2004, National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study, Circulation, 110, 1251, 10.1161/01.CIR.0000140762.04598.F9 Lorenzo, 2007, The National Cholesterol Education Program Adult Treatment Panel III, International Diabetes Foundation and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes, Diabetes Care, 30, 8, 10.2337/dc06-1414 Davis, 2006, Evolving treatments for cardiometabolic syndrome, Manag Care Med, 9, 17, 10.1097/00003246-198101000-00005 Michos, 2006, Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women, Atherosclerosis, 184, 201, 10.1016/j.atherosclerosis.2005.04.004 Santos, 2007, Metabolic syndrome is associated with coronary artery calcium in asymptomatic white Brazilian men considered low-risk by Framingham risk score, Prev Cardiol, 10, 141, 10.1111/j.1520-037X.2007.888128.x Shaw, 2003, Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality, Radiology, 228, 826, 10.1148/radiol.2283021006 Wang, 2002, C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study, Circulation, 106, 1189, 10.1161/01.CIR.0000032135.98011.C4 Nassis, 2005, Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin and inflammatory markers in overweight and obese girls, Metabolism, 54, 1472, 10.1016/j.metabol.2005.05.013 LaMonte, 2005, Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women, Circulation, 112, 505, 10.1161/CIRCULATIONAHA.104.503805 Lopez-Garcia, 2004, Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction, Am J Clin Nutr, 80, 1029, 10.1093/ajcn/80.4.1029 Esposito, 2004, Effect of Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial, JAMA, 292, 1440, 10.1001/jama.292.12.1440 Ebbeling, 2007, Effects of a low-glycemic load vs low fat diet in obese young adults: a randomized trial, JAMA, 297, 2012, 10.1001/jama.297.19.2092 American Diabetes Association, 2005, Clinical practice recommendations, Diabetes Care, 28, s1 Smith, 2001, AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic vascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology, Circulation, 104, 1577, 10.1161/hc3801.097475 Pearson, 2002, Circulation, 106, 388, 10.1161/01.CIR.0000020190.45892.75 National Institutes of Health, 1998, Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults – the evidence report, Obes Res, 6, 51S Ridker, 2005, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women, N Engl J Med, 352, 1293, 10.1056/NEJMoa050613 Mosca, 2007, Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update, Circulation, 115, 1481, 10.1161/CIRCULATIONAHA.107.181546 Yusuf, 2001, Ramapril and the development of diabetes, JAMA, 286, 1882, 10.1001/jama.286.15.1882 Lindholm, 2002, Risk of new-onset diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study, J Hypertens, 20, 1879, 10.1097/00004872-200209000-00035 Kjeldsen, 2006, Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high risk hypertensive patients: the VALUE trial, J Hypertens, 24, 1045, 10.1097/01.hjh.0000234122.55895.5b